Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Kevin Kelly, MD

    TitleAssociate Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressNOR 1441 Eastlake Ave
    Health Sciences Campus
    Los Angeles California 90033
    Phone+1 323 865 3828
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Kelly is a hematologist with clinical expertise in phase I investigational therapeutics and hematological malignancies, including lymphoma and multiple myeloma. His research focuses on understanding the mechanisms of resistance to chemotherapy in hematological malignancies and the use of novel agents to overcome this resistance, and he has published extensively in peer-reviewed journals. Through collaborations with a large team of scientists, he has translated preclinical discoveries into novel clinical trials including an investigator-initiated study of the phosphodiesterase 4B inhibitor, roflumilast, in B cell lymphoproliferative disorders.

      Dr. Kelly earned his medical degree and PhD from University College Cork. He then went on to complete an Advanced Drug Development Clinical Fellowship at The University of Texas Health Science Center.


      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      ASCO/AACR Workshop on Methods in Clinical Cancer Research2009Travel Award
      EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer2011Travel Award
      National Cancer Institute2016Cancer Clinical Investigator Team Leadership Award

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Siddiqi IN, Friedman J, Barry-Holson KQ, Ma C, Thodima V, Kang I, Padmanabhan R, Dias LM, Kelly K, Brynes RK, Kamalakaran S, Houldsworth J. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol. 2016 Jun; 29(6):570-81. PMID: 26965583.
        View in: PubMed
      2. Kelly K, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 01; 6(38):41275-89. PMID: 26513296; PMCID: PMC4747405.
        View in: PubMed, PubMed Central
      3. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 01; 22(1):34-43. PMID: 26561559.
        View in: PubMed
      4. Merin NM, Kelly K. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel). 2014 Dec 24; 8(1):1-20. PMID: 25545164; PMCID: PMC4381198.
        View in: PubMed, PubMed Central
      5. Nawrocki ST, Kelly K, Smith PG, Keaton M, Carraway H, Sekeres MA, Maciejewski JP, Carew JS. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin Cancer Res. 2015 Jan 15; 21(2):439-47. PMID: 25388161; PMCID: PMC4297545.
        View in: PubMed, PubMed Central
      6. Nawrocki ST, Kelly K, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, Carew JS. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3577-90. PMID: 23633453.
        View in: PubMed
      7. Carew JS, Kelly K, Nawrocki ST. Autophagy as a target for cancer therapy: new developments. Cancer Manag Res. 2012; 4:357-65. PMID: 23091399; PMCID: PMC3474143.
        View in: PubMed, PubMed Central
      8. Nawrocki ST, Griffin P, Kelly K, Carew JS. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012 Oct; 21(10):1563-73. PMID: 22799561.
        View in: PubMed
      9. Kelly K, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, Ecsedy J, Giles FJ, Carew JS. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer. 2012 Dec 01; 131(11):2693-703. PMID: 22488249; PMCID: PMC3419336.
        View in: PubMed, PubMed Central
      10. Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. The Pim kinases: new targets for drug development. Curr Drug Targets. 2011 Dec; 12(14):2059-66. PMID: 21777193.
        View in: PubMed
      11. Kelly K, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS. Targeting aurora kinases in cancer treatment. Curr Drug Targets. 2011 Dec; 12(14):2067-78. PMID: 21777198.
        View in: PubMed
      12. Kelly K, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011 Oct; 15(10):2057-70. PMID: 21091633; PMCID: PMC4394217.
        View in: PubMed, PubMed Central
      13. Kelly K, Espitia CM, Taverna P, Choy G, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol. 2012 Jan; 156(1):129-32. PMID: 21689092.
        View in: PubMed
      14. Kelly K, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011 Mar; 6(1):53-61. PMID: 21499765.
        View in: PubMed
      15. Carew JS, Kelly K, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011 Mar; 6(1):17-27. PMID: 21547705.
        View in: PubMed
      16. Carew JS, Espitia CM, Esquivel JA, Mahalingam D, Kelly K, Reddy G, Giles FJ, Nawrocki ST. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25; 286(8):6602-13. PMID: 21148553; PMCID: PMC3057822.
        View in: PubMed, PubMed Central
      17. Carew JS, Medina EC, Esquivel JA, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2010 Oct; 14(10):2448-59. PMID: 19583815; PMCID: PMC2891399.
        View in: PubMed, PubMed Central
      18. Swords RT, Kelly K, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010 May 06; 115(18):3796-800. PMID: 20203261.
        View in: PubMed
      19. Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. Cdc7 kinase - a new target for drug development. Eur J Cancer. 2010 Jan; 46(1):33-40. PMID: 19815406.
        View in: PubMed
      20. Mahalingam D, Medina EC, Esquivel JA, Espitia CM, Smith S, Oberheu K, Swords R, Kelly K, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010 Jan 01; 16(1):141-53. PMID: 20028765.
        View in: PubMed
      21. Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Reovirus-based therapy for cancer. Expert Opin Biol Ther. 2009 Jul; 9(7):817-30. PMID: 19527106.
        View in: PubMed
      22. Mahalingam D, Kelly K, Swords RT, Carew J, Nawrocki ST, Giles FJ. Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs. 2009 Jun; 14(2):311-28. PMID: 19466902.
        View in: PubMed
      Kevin's Networks
      Concepts
      Derived automatically from this person's publications.
      See all (127) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (3) people
      _
      Similar People
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department